May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC
Apr 6, 2025, 10:38

Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC

Seyed Alireza Javadinia, V, shared an article by Paolo Bossiet al. on LinkedIn:

“The I-TACKLE trial by Paolo Bossi; Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC:

Median treatment durations were 3 months (pembrolizumab) and 4 months (combination).

Highlights:

1. Cetuximab overcame pembrolizumab resistance, reaching a 63 % cumulative ORR.
2. Cetuximab reversed primary/acquired resistance in 43 % of cSCC cases, with safety.”

Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial.

Authors: Paolo Bossi, et al.

Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC